|
|||||||
|
|
|
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
|
|
BIOD
STK
NNOX
PBL
ANY
FCLD
LUV
BURU
DAEG
HKTV
NULC
WINT
|
Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy |
Refund Policy | Disclaimer